|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wang Y, Zhu Y, Zhang L, Tian W, Hua S,
Zhao J, Zhang H and Xue F: Insulin promotes proliferation,
survival, and invasion in endometrial carcinoma by activating the
MEK/ERK pathway. Cancer Lett. 322:223–231. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
de Boer SM, Powell ME, Mileshkin L,
Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA,
Khaw P, Colombo A, et al: Toxicity and quality of life after
adjuvant chemoradiotherapy versus radiotherapy alone for women with
high-risk endometrial cancer (PORTEC-3): An open label,
multicentre, randomised, phase 3 trial. Lancet Oncol. 17:1114–1126.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liang H, Cheung LW, Li J, Ju Z, Yu S,
Stemke-Hale K, Dogruluk T, Lu Y, Liu X, Gu C, et al: Whole-exome
sequencing combined with functional genomics reveals novel
candidate driver cancer genes in endometrial cancer. Genome Res.
22:2120–2129. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mao TL, Ardighieri L, Ayhan A, Kuo KT, Wu
CH, Wang TL and Shih IeM: Loss of ARID1A expression correlates with
stages of tumor progression in uterine endometrioid carcinoma. Am J
Surg Pathol. 37:1342–1348. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Er TK, Su YF, Wu CC, Chen CC, Wang J,
Hsieh TH, Herreros-Villanueva M, Chen WT, Chen YT, Liu TC, et al:
Targeted next-generation sequencing for molecular diagnosis of
endometriosis-associated ovarian cancer. J Mol Med (Berl).
94:835–847. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wiegand KC, Shah SP, Al-Agha OM, Zhao Y,
Tse K, Zeng T, Senz J, McConechy MK, Anglesio MS, Kalloger SE, et
al: ARID1A mutations in endometriosis-associated ovarian
carcinomas. N Engl J Med. 363:1532–1543. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jones S, Wang TL, Shih IeM, Mao TL,
Nakayama K, Roden R, Glas R, Slamon D, Diaz LA Jr, Vogelstein B, et
al: Frequent mutations of chromatin remodeling gene ARID1A in
ovarian clear cell carcinoma. Science. 330:228–231. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhai Y, Kuick R, Tipton C, Wu R, Sessine
M, Wang Z, Baker SJ, Fearon ER and Cho KR: Arid1a inactivation in
an Apc- and Pten-defective mouse ovarian cancer model enhances
epithelial differentiation and prolongs survival. J Pathol.
238:21–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ayhan A, Mao TL, Seckin T, Wu CH, Guan B,
Ogawa H, Futagami M, Mizukami H, Yokoyama Y, Kurman RJ and Shih
IeM: Loss of ARID1A expression is an early molecular event in tumor
progression from ovarian endometriotic cyst to clear cell and
endometrioid carcinoma. Int J Gynecol Cancer. 22:1310–1315. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wu JN and Roberts CW: ARID1A mutations in
cancer: Another epigenetic tumor suppressor? Cancer Discov.
3:35–43. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Arocho A, Chen B, Ladanyi M and Pan Q:
Validation of the 2-DeltaDeltaCt calculation as an alternate method
of data analysis for quantitative PCR of BCR-ABL P210 transcripts.
Diagn Mol Pathol. 15:56–61. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zang ZJ, Cutcutache I, Poon SL, Zhang SL,
McPherson JR, Tao J, Rajasegaran V, Heng HL, Deng N, Gan A, et al:
Exome sequencing of gastric adenocarcinoma identifies recurrent
somatic mutations in cell adhesion and chromatin remodeling genes.
Nat Genet. 44:570–574. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gagnon V, Mathieu I, Sexton E, Leblanc K
and Asselin E: AKT involvement in cisplatin chemoresistance of
human uterine cancer cells. Gynecol Oncol. 94:785–795. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Trabert B, Wentzensen N, Felix AS, Yang
HP, Sherman ME and Brinton LA: Metabolic syndrome and risk of
endometrial cancer in the United States: A study in the
SEER-medicare linked database. Cancer Epidemiol Biomarkers Prev.
24:261–267. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Stocks T, Bjørge T, Ulmer H, Manjer J,
Häggström C, Nagel G, Engeland A, Johansen D, Hallmans G, Selmer R,
et al: Metabolic risk score and cancer risk: Pooled analysis of
seven cohorts. Int J Epidemiol. 44:1353–1363. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang Y, Hua S, Tian W, Zhang L, Zhao J,
Zhang H, Zhang W and Xue F: Mitogenic and anti-apoptotic effects of
insulin in endometrial cancer are phosphatidylinositol 3-kinase/Akt
dependent. Gynecol Oncol. 125:734–741. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
McCampbell AS, Walker CL, Broaddus RR,
Cook JD and Davies PJ: Developmental reprogramming of IGF signaling
and susceptibility to endometrial hyperplasia in the rat. Lab
Invest. 88:615–626. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Le Roith D: The insulin-like growth factor
system. Exp Diabesity Res. 4:205–212. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bruchim I, Sarfstein R, Reiss A, Flescher
E and Werner H: IGF1R tyrosine kinase inhibitor enhances the
cytotoxic effect of methyl jasmonate in endometrial cancer. Cancer
Lett. 352:214–219. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang Y, Gao C, Zhang Y, Gao J, Teng F,
Tian W, Yang W, Yan Y and Xue F: Visfatin stimulates endometrial
cancer cell proliferation via activation of PI3K/Akt and
MAPK/ERK1/2 signalling pathways. Gynecol Oncol. 143:168–178. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ogawa K, Sun C and Horii A: Exploration of
genetic alterations in human endometrial cancer and melanoma:
Distinct tumorigenic pathways that share a frequent abnormal
PI3K/AKT cascade. Oncol Rep. 14:1481–1485. 2005.PubMed/NCBI
|
|
23
|
Li Y, Jia Y, Che Q, Zhou Q, Wang K and Wan
XP: AMF/PGI-mediated tumorigenesis through MAPK-ERK signaling in
endometrial carcinoma. Oncotarget. 6:26373–26387. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tao Y, Pinzi V, Bourhis J and Deutsch E:
Mechanisms of disease: Signaling of the insulin-like growth factor
1 receptor pathway-therapeutic perspectives in cancer. Nat Clin
Pract Oncol. 4:591–602. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ewing GP and Goff LW: The insulin-like
growth factor signaling pathway as a target for treatment of
colorectal carcinoma. Clin Colorectal Cancer. 9:219–223. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tognon CE and Sorensen PH: Targeting the
insulin-like growth factor 1 receptor (IGF1R) signaling pathway for
cancer therapy. Expert Opin Ther Targets. 16:33–48. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Campbell M, Allen WE, Sawyer C,
Vanhasebroeck B and Trimble ER: Glucose-potentiated chemotaxis in
human vascular smooth muscle is dependent on cross-talk between the
PI3K and MAPK signaling pathways. Circ Res. 95:380–388. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ward EC, Hoekstra AV, Blok LJ,
Hanifi-Moghaddam P, Lurain JR, Singh DK, Buttin BM, Schink JC and
Kim JJ: The regulation and function of the forkhead transcription
factor, Forkhead box O1, is dependent on the progesterone receptor
in endometrial carcinoma. Endocrinology. 149:1942–1950. 2008.
View Article : Google Scholar : PubMed/NCBI
|
